Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Adebrelimab Plus Etoposide and Cisplatin in Neuroendocrine Bladder Carcinoma
NCT06091124Phase 2Recruiting
- Sponsor
- Renji Hospital
- Start
- Nov 2023
- Primary completion
- Jan 2027
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of adebrelimab in neuroendocrine carcinoma of the bladder, sponsored by Renji Hospital. Started Nov 2023; status: recruiting.
02
Drugs
adebrelimab
03
Conditions
neuroendocrine carcinoma of the bladder
Beyond the preview
Go deeper on NCT06091124.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06091124.